We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fresenius Medical's (FMS) New Dialyzer to Boost Patient Outcome
Read MoreHide Full Article
Fresenius Medical Care AG & Co. (FMS - Free Report) recently announced that it is launching a new dialyzer for hemodialysis, the FX CorAL— the newest dialyzer in the company’s FX class of dialyzers which use polysulfone (a special plastic with exceptional filtering and hemocompatibility characteristics). The FX CorAL was unveiled in Fresenius Medical Care’s NephroCare clinics after it received the CE mark, and has already been used in more than three million treatments.
For investors’ note, the FX CorAL is already available in Switzerland and will be gradually launched in Germany, France, Italy and the United Arab Emirates. Other countries in the company’s Europe, Middle East and Africa region will follow.
The latest launch is expected to significantly solidify Fresenius Medical’s business on a global scale.
Significance of the Launch
The highlight of the FX CorAL dialyzer is its clinical performance and hemocompatibility. It is noteworthy to mention that dialysis patients often suffer from chronic inflammation caused by the accumulation of toxic substances and the regular contact of their blood with external substances. These inflammations reduce patients’ quality of life and lead to the onset of cardiovascular diseases.
The design of the FX CorAL dialyzer is such that it absorbs lower proteins, thereby achieving a lower induction of the immune response in the patient while maintaining high selective permeability for the removal of toxins and excess water. Additionally, all FX-class dialyzers are steam-sterilized and environment friendly.
Per management, combining clinical performance with hemocompatibility is expected to significantly improve treatment quality of the company’s dialysis patients, thereby enhancing the patients’ well-being.
Industry Prospects
Per a report published by Market Reports World, the global dialyzer market was valued at $6535 million in 2020 and is expected to reach $10210 million by the end of 2027 at a CAGR of 6.6%. Factors like rise in elderly population and surge in incidence of renal diseases (especially end stage renal disease) are likely to drive the market.
Given the market potential, the latest launch is expected to significantly boost Fresenius Medical’s business on a global scale.
Notable Development
In November, Fresenius Medical announced its third-quarter 2021 financial results, where it registered revenue growth across EMEA, Asia Pacific and Latin America regions.
Price Performance
Shares of the company have lost 29.2% in the past year against the industry’s 8.2% rise and the S&P 500 composite’s 27.6% growth.
Image Source: Zacks Investment Research
Zacks Rank & Stocks to Consider
Currently, Fresenius Medical carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are AmerisourceBergen Corporation , Thermo Fisher Scientific Inc. (TMO - Free Report) and AMN Healthcare Services (AMN - Free Report) .
AmerisourceBergen, carrying a Zacks Rank #2 (Buy), reported fourth-quarter fiscal 2021 adjusted earnings per share (EPS) of $2.39, which beat the Zacks Consensus Estimate by 1.3%. Revenues of $58.91 billion outpaced the consensus mark by 3.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AmerisourceBergen has an estimated long-term growth rate of 11.3%. The company surpassed estimates in the trailing four quarters, the average surprise being 5.48%.
Thermo Fisher reported third-quarter 2021 adjusted EPS of $5.76, which surpassed the Zacks Consensus Estimate by 23.3%. Third-quarter revenues of $9.33 billion outpaced the Zacks Consensus Estimate by 12%. It currently carries a Zacks Rank #2.
Thermo Fisher has an estimated long-term growth rate of 14%. The company surpassed estimates in the trailing four quarters, the average surprise being 9.02%.
AMN Healthcare reported third-quarter 2021 adjusted EPS of $1.73, which surpassed the Zacks Consensus Estimate by 29.1%. Third-quarter revenues of $877.8 million outpaced the Zacks Consensus Estimate by 12.3%. It currently sports a Zacks Rank #1.
AMN Healthcare has an estimated long-term growth rate of 16.2%. The company surpassed estimates in the trailing four quarters, the average surprise being 19.51%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Fresenius Medical's (FMS) New Dialyzer to Boost Patient Outcome
Fresenius Medical Care AG & Co. (FMS - Free Report) recently announced that it is launching a new dialyzer for hemodialysis, the FX CorAL— the newest dialyzer in the company’s FX class of dialyzers which use polysulfone (a special plastic with exceptional filtering and hemocompatibility characteristics). The FX CorAL was unveiled in Fresenius Medical Care’s NephroCare clinics after it received the CE mark, and has already been used in more than three million treatments.
For investors’ note, the FX CorAL is already available in Switzerland and will be gradually launched in Germany, France, Italy and the United Arab Emirates. Other countries in the company’s Europe, Middle East and Africa region will follow.
The latest launch is expected to significantly solidify Fresenius Medical’s business on a global scale.
Significance of the Launch
The highlight of the FX CorAL dialyzer is its clinical performance and hemocompatibility. It is noteworthy to mention that dialysis patients often suffer from chronic inflammation caused by the accumulation of toxic substances and the regular contact of their blood with external substances. These inflammations reduce patients’ quality of life and lead to the onset of cardiovascular diseases.
The design of the FX CorAL dialyzer is such that it absorbs lower proteins, thereby achieving a lower induction of the immune response in the patient while maintaining high selective permeability for the removal of toxins and excess water. Additionally, all FX-class dialyzers are steam-sterilized and environment friendly.
Per management, combining clinical performance with hemocompatibility is expected to significantly improve treatment quality of the company’s dialysis patients, thereby enhancing the patients’ well-being.
Industry Prospects
Per a report published by Market Reports World, the global dialyzer market was valued at $6535 million in 2020 and is expected to reach $10210 million by the end of 2027 at a CAGR of 6.6%. Factors like rise in elderly population and surge in incidence of renal diseases (especially end stage renal disease) are likely to drive the market.
Given the market potential, the latest launch is expected to significantly boost Fresenius Medical’s business on a global scale.
Notable Development
In November, Fresenius Medical announced its third-quarter 2021 financial results, where it registered revenue growth across EMEA, Asia Pacific and Latin America regions.
Price Performance
Shares of the company have lost 29.2% in the past year against the industry’s 8.2% rise and the S&P 500 composite’s 27.6% growth.
Zacks Rank & Stocks to Consider
Currently, Fresenius Medical carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are AmerisourceBergen Corporation , Thermo Fisher Scientific Inc. (TMO - Free Report) and AMN Healthcare Services (AMN - Free Report) .
AmerisourceBergen, carrying a Zacks Rank #2 (Buy), reported fourth-quarter fiscal 2021 adjusted earnings per share (EPS) of $2.39, which beat the Zacks Consensus Estimate by 1.3%. Revenues of $58.91 billion outpaced the consensus mark by 3.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AmerisourceBergen has an estimated long-term growth rate of 11.3%. The company surpassed estimates in the trailing four quarters, the average surprise being 5.48%.
Thermo Fisher reported third-quarter 2021 adjusted EPS of $5.76, which surpassed the Zacks Consensus Estimate by 23.3%. Third-quarter revenues of $9.33 billion outpaced the Zacks Consensus Estimate by 12%. It currently carries a Zacks Rank #2.
Thermo Fisher has an estimated long-term growth rate of 14%. The company surpassed estimates in the trailing four quarters, the average surprise being 9.02%.
AMN Healthcare reported third-quarter 2021 adjusted EPS of $1.73, which surpassed the Zacks Consensus Estimate by 29.1%. Third-quarter revenues of $877.8 million outpaced the Zacks Consensus Estimate by 12.3%. It currently sports a Zacks Rank #1.
AMN Healthcare has an estimated long-term growth rate of 16.2%. The company surpassed estimates in the trailing four quarters, the average surprise being 19.51%.